全文获取类型
收费全文 | 4409篇 |
免费 | 319篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 55篇 |
妇产科学 | 93篇 |
基础医学 | 543篇 |
口腔科学 | 76篇 |
临床医学 | 396篇 |
内科学 | 987篇 |
皮肤病学 | 75篇 |
神经病学 | 470篇 |
特种医学 | 193篇 |
外科学 | 711篇 |
综合类 | 58篇 |
一般理论 | 1篇 |
预防医学 | 202篇 |
眼科学 | 50篇 |
药学 | 341篇 |
中国医学 | 52篇 |
肿瘤学 | 455篇 |
出版年
2023年 | 33篇 |
2022年 | 66篇 |
2021年 | 130篇 |
2020年 | 67篇 |
2019年 | 125篇 |
2018年 | 115篇 |
2017年 | 94篇 |
2016年 | 134篇 |
2015年 | 156篇 |
2014年 | 205篇 |
2013年 | 253篇 |
2012年 | 367篇 |
2011年 | 363篇 |
2010年 | 253篇 |
2009年 | 208篇 |
2008年 | 280篇 |
2007年 | 276篇 |
2006年 | 203篇 |
2005年 | 208篇 |
2004年 | 170篇 |
2003年 | 146篇 |
2002年 | 114篇 |
2001年 | 75篇 |
2000年 | 73篇 |
1999年 | 67篇 |
1998年 | 36篇 |
1997年 | 18篇 |
1996年 | 30篇 |
1995年 | 25篇 |
1994年 | 12篇 |
1993年 | 15篇 |
1992年 | 39篇 |
1991年 | 46篇 |
1990年 | 38篇 |
1989年 | 32篇 |
1988年 | 33篇 |
1987年 | 38篇 |
1986年 | 30篇 |
1985年 | 23篇 |
1984年 | 20篇 |
1983年 | 16篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1979年 | 13篇 |
1978年 | 18篇 |
1977年 | 10篇 |
1974年 | 16篇 |
1973年 | 8篇 |
1972年 | 9篇 |
排序方式: 共有4774条查询结果,搜索用时 15 毫秒
91.
BACKGROUND/AIMS: 6-Mercaptopurine and its prodrug azathioprine are effective for the treatment of inflammatory bowel disease. Thiopurine methyltransferase is important for the metabolism of thiopurines. However, there is controversy as to the clinical utility of measuring thiopurine methyltransferase enzyme activity and 6-thioguanine nucleotide levels. Our aim was to determine if thiopurine methyltransferase enzyme activity and 6-thioguanine nucleotide level monitoring would predict response to therapy with thiopurines in patients with inflammatory bowel disease. METHODS: Baseline thiopurine methyltransferase enzyme activity prior to initiation of therapy with either 6-mercaptopurine or azathioprine was determined in 39 patients with inflammatory bowel disease. The association between clinical response and thiopurine methyltransferase activity and 6-thioguanine nucleotide levels singly or in combination were analysed. RESULTS: Seventeen of 39 patients (44%) responded to 6-mercaptopurine or azathioprine therapy. Thiopurine methyltransferase enzyme activity below the mean of 30.5 U was significantly associated with clinical response. The thiopurine methyltransferase low phenotype was associated with response in 65% vs. 29% in individuals with thiopurine methyltransferase enzyme activity above 30.5 U (p = 0.05). There was no correlation between thiopurine methyltransferase activity and 6-thioguanine nucleotide levels. The maximal 6-thioguanine nucleotide levels did not predict clinical response. When combining thiopurine methyltransferase enzyme activity and 6-thioguanine nucleotide levels, the combination of thiopurine methyltransferase low/6-thioguanine nucleotide high was associated with response in 7/7 (100%) vs. only 2/8 (25%) with the combination of thiopurine methyltransferase high/6-thioguanine nucleotide low (p=0.01). CONCLUSIONS: Thiopurine methyltransferase activity inversely correlated with clinical response to thiopurine treatment in inflammatory bowel disease. Thiopurine methyltransferase enzyme activity below 30.5 U combined with a post-treatment 6-thioguanine nucleotide level > 230 pmol/8 x 10(8) erythrocytes was the best predictor of response. 相似文献
92.
Yvonne T Tsang Michael T Deavers Charlotte C Sun Suet‐Yan Kwan Eric Kuo Anais Malpica Samuel C Mok David M Gershenson Kwong‐Kwok Wong 《The Journal of pathology》2013,231(4):449-456
BRAF and KRAS mutations in ovarian serous borderline tumours (OSBTs) and ovarian low‐grade serous carcinomas (LGSCs) have been previously described. However, whether those OSBTs would progress to LGSCs or whether those LGSCs were developed from OSBT precursors in previous studies is unknown. Therefore, we assessed KRAS and BRAF mutations in tumour samples from 23 recurrent LGSC patients with a known initial diagnosis of OSBT. Paraffin blocks from both OSBT and LGSC samples were available for five patients, and either OSBTs or LGSCs were available for another 18 patients. Tumour cells from paraffin‐embedded tissues were dissected out for mutation analysis by conventional polymerase chain reaction (PCR) and Sanger sequencing. Tumours that appeared to have wild‐type KRAS by conventional PCR–Sanger sequencing were further analysed by full COLD (co‐amplification at lower denaturation temperature)‐PCR and deep sequencing. Full COLD‐PCR was able to enrich the amplification of mutated alleles. Deep sequencing was performed with the Ion Torrent personal genome machine (PGM). By conventional PCR–Sanger sequencing, BRAF mutation was detected only in one patient and KRAS mutations were detected in ten patients. Full COLD‐PCR deep sequencing detected low‐abundance KRAS mutations in eight additional patients. Three of the five patients with both OSBT and LGSC samples available had the same KRAS mutations detected in both OSBT and LGSC samples. The remaining two patients had only KRAS mutations detected in their LGSC samples. For patients with either OSBT or LGSC samples available, KRAS mutations were detected in seven OSBT samples and six LGSC samples. Surprisingly, patients with the KRAS G12V mutation have shorter survival times. In summary, KRAS mutations are very common in recurrent LGSC, while BRAF mutations are rare. The findings indicate that recurrent LGSC can arise from proliferation of OSBT tumour cells with or without detectable KRAS mutations. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
93.
Ranawaka A. P. M. Perera Ronald Ko Owen T. Y. Tsang David S. C. Hui Mike Y. M. Kwan Christopher J. Brackman Esther M. W. To Hui-ling Yen Kathy Leung Samuel M. S. Cheng Kin Ho Chan Karl C. K. Chan Ka-Chi Li Linda Saif Vanessa R. Barrs Joseph T. Wu Thomas H. C. Sit Leo L. M. Poon Malik Peiris 《Journal of clinical microbiology》2021,59(2)
94.
Kyung Jin Ahn Jongwook Yu Albert Youngwoo Jang Dae-Hyeok Kim Jun Kwan Wook-Jin Chung 《Yonsei medical journal》2021,62(5):391
PurposeHeart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in HF. We aimed to determine the effectiveness of force-titration of valsartan on VVI values in HF patients.Materials and MethodsIn this multicenter and prospective observational trial, the effect of valsartan was stratified according to dosages [non-ceiling dose (NCD) vs. ceiling dose (CD)] in HF patients with left ventricular ejection fraction (LVEF) <55%. Biochemical studies, including N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography with VVI, the treadmill test, and the activity scale index were assessed at baseline and after 24 weeks of treatment.ResultsOne-hundred thirty-eight patients were force-titrated to either a CD group (n=81) or a NCD group (n=57). The mean age of the study participants was 59 years and 66% were male. After 6 months of follow up, left ventricular mass index (LVMI) values had significantly improved in the CD group but not in the NCD group. Intriguingly, in HF patients with a reduced ejection fraction (HFrEF) (n=52, LVEF <40%), a significant improvement in VVI was only observed in the CD group (from 2.4±0.6 to 1.8±0.5, p<0.001).ConclusionCDs of valsartan for 6 months showed better improvement in VVI, as well as LVMI, in patients with HFrEF, compared with NCDs. 相似文献
95.
Kyung Soo Hong Kwan Ho Lee Jin Hong Chung Kyeong-Cheol Shin Hyun Jung Jin Jong Geol Jang June Hong Ahn 《Journal of Korean medical science》2021,36(24)
BackgroundThe presence of the bronchus sign on chest computed tomography is associated with an increased diagnostic yield of radial probe endobronchial ultrasound–guided transbronchial lung biopsy (RP-EBUS-TBLB). However, the utility of RP-EBUS-TBLB for bronchus sign negative peripheral pulmonary lesions (PPLs) remains unknown. We investigated the utility of RP-EBUS-TBLB in bronchus sign negative PPLs.MethodsWe retrospectively reviewed data from 109 patients who underwent RP-EBUS for bronchus sign negative PPLs from January 2019 to August 2020. TBLB was performed using RP-EBUS with a guide sheath and without fluoroscopy. The EBUS visualization and TBLB diagnostic yields were assessed. Multivariable logistic regression analyses were used to identify factors affecting the EBUS visualization and diagnostic yields.ResultsThe EBUS visualization yield was 74.1% (68/109). Of the 109 lung lesions, 92 were definitively diagnosed. The overall diagnostic accuracy, sensitivity, specificity, positive predictive value, and negative predictive value were 50.5% (55/109), 34.9% (29/83), 100% (26/26), 100% (29/29), and 32.5% (26/80), respectively. In multivariable analyses, the size of the lesion (≥ 20 mm; odds ratio [OR], 2.62; 95% confidence interval [CI], 1.16–5.93; P = 0.021) and the distance from the pleura (> 10 mm; OR, 2.37; 95% CI, 1.02–5.52; P = 0.045) were associated with EBUS visualization. Regarding diagnostic yield, having the probe within the lesion (OR, 28.50; 95% CI, 6.26–129.85; P < 0.001) and a solid lesion (OR, 14.58; 95% CI, 2.64–80.38; P = 0.002) were associated with diagnostic success. Pneumothorax and hemoptysis occurred in 3.7% (4/109) and 0.9% (1/109), respectively, of the patients.ConclusionRP-EBUS-TBLB using a GS can be considered a diagnostic method in bronchus sign negative solid PPLs. Having the probe within the lesion and a solid lesion were important for diagnostic success. Complication rates were acceptable. 相似文献
96.
Irini Manoli Justin Y. Kwan Qian Wang Elisabeth J. Rushing Maria Tsokos Andrew E. Arai Warner M. Burch Angela Dispenzieri Alexandra C. McPherron William A. Gahl 《Molecular genetics and metabolism》2013,108(4):249-254
Amyloid myopathy associated with a plasma cell dyscrasia is a rare cause of muscle hypertrophy. It can be a challenging diagnosis, since pathological findings are often elusive. In addition, the mechanism by which immunoglobulin light-chain deposition stimulates muscle overgrowth remains poorly understood. We present a 53-year old female with a 10-year history of progressive generalized muscle overgrowth. Congo-red staining and immunohistochemistry revealed perivascular lambda light chain amyloid deposits, apparent only in a second muscle biopsy. The numbers of central nuclei and satellite cells were increased, suggesting enhanced muscle progenitor cell formation. Despite the chronicity of the light chain disease, the patient showed complete resolution of hematologic findings and significant improvement of her muscle symptoms following autologous bone marrow transplantation. This case highlights the importance of early diagnosis and therapy for this treatable cause of a chronic myopathy with muscle hypertrophy. 相似文献
97.
Jacqueline Lorene Bender Rossini Ying Kwan Yue Matthew Jason To Laetitia Deacken Alejandro R Jadad 《Journal of medical Internet research》2013,15(12)
Background
Mobile phones have become nearly ubiquitous, offering a promising means to deliver health interventions. However, little is known about smartphone applications (apps) for cancer.Objective
The purpose of this study was to characterize the purpose and content of cancer-focused smartphone apps available for use by the general public and the evidence on their utility or effectiveness.Methods
We conducted a systematic review of the official application stores for the four major smartphone platforms: iPhone, Android, Nokia, and BlackBerry. Apps were included in the review if they were focused on cancer and available for use by the general public. This was complemented by a systematic review of literature from MEDLINE, Embase, and the Cochrane Library to identify evaluations of cancer-related smartphone apps.Results
A total of 295 apps from the smartphone app stores met the inclusion criteria. The majority of apps targeted breast cancer (46.8%, 138/295) or cancer in general (28.5%, 84/295). The reported app purpose was predominantly to raise awareness about cancer (32.2%, 95/295) or to provide educational information about cancer (26.4%, 78/295), followed by apps to support fundraising efforts (12.9%, 38/295), assist in early detection (11.5%, 34/295), promote a charitable organization (10.2%, 30/295), support disease management (3.7%, 11/295), cancer prevention (2.0%, 6/295), or social support (1.0%, 3/295). The majority of the apps did not describe their organizational affiliation (64.1%, 189/295). Apps affiliated with non-profit organizations were more likely to be free of cost (χ2 1=16.3, P<.001) and have a fundraising or awareness purpose (χ2 2=13.3, P=.001). The review of the health literature yielded 594 articles, none of which reported an evaluation of a cancer-focused smartphone application.Conclusions
There are hundreds of cancer-focused apps with the potential to enhance efforts to promote behavior change, to monitor a host of symptoms and physiological indicators of disease, and to provide real-time supportive interventions, conveniently and at low cost. However, there is a lack of evidence on their utility, effectiveness, and safety. Future efforts should focus on improving and consolidating the evidence base into a whitelist for public consumption. 相似文献98.
99.